| Document |
Document Title |
|
WO/2001/056358A2 |
This invention relates to enhanced propertied pesticides which can be used as fungicides, herbicides, insecticides, rodenticides or biocides, compositions comprising enhanced propertied pesticides, and the method of use of enhanced prope...
|
|
WO/2001/056975A1 |
The invention concerns novel substituted imide derivatives of general formula (I), wherein R?1¿ represents optionally substituted cycloalkyl; R?2¿ represents optionally substituted alkyl or optionally substituted cycloalkyl; R?3¿ repr...
|
|
WO/2001/056980A1 |
A process, for the preparation of an ester of 2-hydroxy-4-methylthiobutyric acid which is substantially in the monomeric form, which process, being capable of industrial application and which comprises reacting 2-hydroxy-4-methylthiobuty...
|
|
WO/2001/054481A2 |
This invention relates to compounds which are useful as enhanced propertied pharmaceutical compounds for both human and veterinary application. The pharmaceutical compounds which are suitable for use in this invention are those compounds...
|
|
WO/2001/055082A2 |
|
|
WO/2001/053279A1 |
A compound of formula (I) where D is a VLA-4 specificity determinant which does not impart significant IIB/IIIa activity; R?41¿ is a group of the formula (V): U - (CH¿2?)¿d? - V - T wherein U is selected from oxygen, sulphur, a direct...
|
|
WO/2001/051456A2 |
Hydroxyamidines and related compounds are provided which are suitable as antibacterial agents.
|
|
WO/2001/049275A2 |
Methods and therapeutic compounds for treating pain, mitigating inflammation, effecting analgesia and/or effecting sedation in a subject are described. A subject is administered an effective amount of a therapeutic compound which is a ni...
|
|
WO/2001/047859A1 |
This invention relates to novel compounds that are liver selective glucocorticoid receptor antagonists, to methods of preparing such compounds, and to methods for using such compounds in therapy and in the regulation of metabolism, espec...
|
|
WO/2001/047469A2 |
A method of reducing oxidative stress in the brain of an organism having a blood brain barrier and suffering an ischemic brain injury, the method comprising the step of administering a compound to the organism, the compound having (a) a ...
|
|
WO/2001/047868A1 |
A phenylalanine derivative of formula (1-1) or analogues thereof exhibit an $g(a)¿4?$g(b)¿7? integrin inhibiting activity and selectivity for $g(a)¿4?$g(b)¿1? integrin, thus being useful as remedies for various diseases related to $g...
|
|
WO/2001/047863A2 |
The invention relates to aryl vinyl ether compounds of formula (I) wherein R?1¿, R?2¿ and Y are as defined in the description; to compositions containing them, processes and intermediates for their preparation and a method of controlli...
|
|
WO/2001/046124A1 |
Aromatic diamide derivatives of general formula (I) or salts thereof; chemicals for agricultural or horticultural use; and usage thereof [wherein A?1¿ is optionally substituted C¿1-8? alkylene, C¿3-8? alkenylene, or the like; B is O- ...
|
|
WO/2001/045703A1 |
The present invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitors and novel compositions comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitor, and, optionally, a...
|
|
WO/2001/046127A1 |
The invention specifically concerns pseudopeptides derived from functionalised amino acids, comprising fatty acid chains fixed in the form of amide on the amine functions of the pseudopeptide and whereof one of the ends bears a functiona...
|
|
WO/2001/046126A1 |
The invention relates in particular to pseudodipeptides which are derived from functionalised aminoacids and which comprise fatty acid chains that are fixed on the amine functions of the pseudodipeptides in amide form, one of the ends of...
|
|
WO/2001/045836A2 |
A method for identifying molecules and designing novel pharmaceuticals is disclosed. The disclosed method of novel pharmaceutical design identifies a novel chemical group that triggers a mechanism of action for an identified reaction, th...
|
|
WO1999063937A9 |
Disclosed are multibinding compounds which include macrolide antibiotics, aminoglycosides, lincosamides, oxazolidinones, streptogramins, tetracycline and/or other compounds which bind to bacterial ribosomal RNA and/or to one or more prot...
|
|
WO/2001/044164A1 |
The invention relates to substituted norbornylamino derivatives containing exo-configured nitrogen and an endo-annellated pentacyclic ring of formula (I) and exo-configured nitrogen and an exo-annellated pentacyclic ring of formula (Ia),...
|
|
WO/2001/044154A1 |
Dihalopropenyloxybenzene derivatives represented general formula (I) which have a very excellent effect of controlling pests in the field of agriculture, horticulture, daily life, livestock, pets, etc. (in particular, injurious insects a...
|
|
WO/2001/044170A1 |
The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I)...
|
|
WO/2001/042194A1 |
The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy.
|
|
WO/2001/041702A2 |
The invention concerns zinc thiosalicylate in micronized form as dermo-cosmetic product in particular for treating acne and/or seborrheic dermatitis.
|
|
WO/2001/040175A1 |
A process for producing a sulfur compound bearing at least one thio group in the molecule by reacting a thiol compound with an organic compound bearing at least one functional group capable of reacting with a mercapto group to thereby fo...
|
|
WO/2001/040187A2 |
Neuroprotective agents are disclosed having structure: (I) and stereoisomers and pharmaceutically acceptable salts thereof, wherein R¿1? is alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle,...
|
|
WO/2001/039769A1 |
Hypoglycemics having a lower toxicity than vanadium and an adequate stability and exerting an adequate fat-soluble insulin-like effect; and medicinal preparations having an insulin-like effect and being useful as preventives and remedies...
|
|
WO/2001/040170A1 |
The present invention relates to certain phenalkyloxy-phenyl derivatives of formula (I) and analogs, to a process for preparing such compounds, having the utility in clinical conditions associated with insulin resistance, to methods for ...
|
|
WO/2001/040176A1 |
A sulfide compound represented by formula [1] (wherein R?1¿ and R?2¿ each represents halogeno or C¿1-4? alkyl; and R?3¿ to R?7¿ each represents hydrogen or C¿1-4? alkyl, provided that R?5¿ and R?6¿ may be and R?6¿ and R?7¿ may ...
|
|
WO/2001/038295A1 |
Sphingosine derivatives represented by general formula (I), or pharmaceutically acceptable salts thereof, wherein R?1¿ and R?2¿ are each hydrogen or the like; Z is NR?7¿ (wherein R?7¿ is hydrogen or the like); Y is oxygen or NR?8¿ (...
|
|
WO/2001/038303A2 |
The invention concerns novel tri-aromatic compounds of general formula (I) and the method for preparing them, and their use in pharmaceutical compositions for use in human or veterinary medicine (in dermatology, cancerology, as well as i...
|
|
WO/2001/038301A1 |
The present invention provides a compound which is (R)-3-(4-chlorobiphenyl-sulfonyl)2-hydroxy-2-(phenylthio)met
hylpropionic acid of formula (Ia) or a pharmaceutical acceptable salt thereof in enantiomerically pure form. The compound is ...
|
|
WO1999064041A9 |
Disclosed are novel multi-binding compounds (agents) which bind to NMDA receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such receptors, thereby modulating the biological processes and/...
|
|
WO/2001/037826A1 |
NPYY5 receptor antagonists which contain compounds represented bygeneral formula (I), prodrugs thereof, pharmaceutically acceptable salts thereof or solvates of the same wherein R?1¿ represents lower alkyl, cycloalkyl, etc.; R?2¿ repre...
|
|
WO/2001/036376A1 |
Phenylalanine derivatives represented by general formula (1) or pharmaceutically acceptable salts thereof: wherein x represents an interatomic bond, -O-, etc.; Y and Z represent each -C(=O)-, etc.; A represents a specific substituted phe...
|
|
WO/2001/036360A1 |
The invention provides novel selective estrogen receptor modulator compounds of general formula (I), wherein R1 and R2, which are the same or different are a) H, halogen, OCH¿3?, OH; or b) (II), where X is O, NH or S; and n is an intege...
|
|
WO/2001/036383A1 |
A process for the production of an aryl sulfamide having formula (I), in which R?1¿, R?2¿ and R?3¿ are each hydrogen, alkyl, cycloalkyl or aryl, provided that at least one of R?1¿, R?2¿ and R¿3? is aryl,which comprises reacting a c...
|
|
WO/2001/036403A1 |
Disclosed are novel aromatic compounds of formula (I) wherein G, X, Ar, L and Q are defined herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chr...
|
|
WO/2001/034563A1 |
A method of preparing a substantially pure enantiomer of an acylanilide such as Casodex$m(3) (bicalutamide) and/or its derivatives includes resolving an intermediate compound having the structure of Formula (I), wherein: R?1¿ is alkyl o...
|
|
WO/2001/034129A2 |
Heteroatom-interrupted HETE derivatives and methods of their use for treating dry eye are disclosed.
|
|
WO/2001/032602A1 |
Provided, among other things, is a compound of Formula (I), wherein, Ar¿1? and Ar¿2? are independently selected aryl groups, optionally substituted with up to five substituents independently selected from the group consisting of alkyl,...
|
|
WO/2001/032604A1 |
Use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the activation of soluble guanylate cyclase, wherein: R¿1? and R¿2? are the same or different and each repre...
|
|
WO/2001/032164A1 |
An inhibitor for 20-hydroxyeicosatetraenoic acid production which comprises as the active ingredient a specific hydroxyformamidine derivative or a pharmacologically acceptable salt thereof. It is useful especially as a remedy for kidney ...
|
|
WO/2001/032606A1 |
There is disclosed a genus of optionally substituted Schiff base condensation products (and the carba analogs thereof) comprising an amino acid component and a benzaldehyde component, that have MIF (macrophage migration inhibitory factor...
|
|
WO/2001/028987A1 |
The present application describes modulators of CCR3 of formula (I) or pharmaceutically acceptable salt forms thereof, useful for the prevention of inflammatory diseases such as asthma and other allergic diseases.
|
|
WO/2001/029126A1 |
Elastomers which have excellent stability to prevent oxidative, thermal, dynamic, light-induced and/or ozone-induced degradation comprise, as stabilizers, at least one compound of the formula (I): [R-S(=O)¿m?-CH¿2?-CH(OH)-CH¿2?]¿n?-N...
|
|
WO/2001/028990A2 |
A method of synthesizing pure enantiomers of acylanalides such as Casodex$m(3) (bicalutamide) and its derivatives includes contacting a compound having a ring structure that, when opened, provides a substituent having the structure of Fo...
|
|
WO/2001/028974A2 |
The invention concerns novel nitroaromatic compounds of general formula (I') wherein: R, R'¿1?, R¿2?, Z and n are as defined in Claim 38. The invention also concerns a method for preparing nitroaromatic compounds nitrated in position 4...
|
|
WO/2001/027098A2 |
The invention relates to a method for producing compounds of general formula (I) wherein R¿1? is selected from the following groups: (a) OR¿5? and (b) mono-, di-, or tri-substituted phenyl; and R¿2? represents a group (C¿1?-C¿6?)alk...
|
|
WO/2001/026807A1 |
A supported catalyst comprises a cationic rhodium (I) complex of formula (1) wherein R?1¿ and R?2¿ are the same or different hydrocarbon groups of up to 30 C atoms, or R?1¿ and R?2¿ are linked to form a ring, and a heterogeneous supp...
|
|
WO/2001/027084A1 |
Disclosed are compounds which are inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the compounds have a structure according to Formula (I), wh...
|
